Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05811754

Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The purpose of this post-marketing commitment safety study is to evaluate the real-world safety of HZ/su vaccine during pregnancy in immunodeficient or immunosuppressed adult pregnant women between 18 and 49 years of age in the United States. The primary outcome of interest is major congenital malformations (MCMs).

Official title: Post-marketing Commitment Safety Study of HZ/su to Evaluate Pregnancy Exposures and Outcomes in Immunodeficient or Immunosuppressed Women Between 18 and 49 Years of Age

Key Details

Gender

FEMALE

Age Range

18 Years - 49 Years

Study Type

OBSERVATIONAL

Enrollment

2844

Start Date

2022-05-09

Completion Date

2028-03-31

Last Updated

2025-11-12

Healthy Volunteers

No

Conditions

Interventions

OTHER

Data collection

This study will be conducted using data provided by U.S. Research Partners in the FDA's Sentinel Surveillance System. Four Research Partners will participate in this study: CVS Health Clinical Trial Services (CTS), Carelon Research, Optum and Harvard Pilgrim Health Care Institute (HPHCI).

Locations (1)

GSK Investigational Site

Canton, Massachusetts, United States